Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut
How this was made
The 30-second read
Why it matters
The 8-K provides fresh, tradable deal-status milestones (SEC effectiveness and stockholder approval) and updates on financial condition and the company’s strategy to out-license or monetize clinical assets while development is paused.
Market read
Traders may reprice Pulmatrix’s merger-close odds and near-term liquidity risk based on the newly disclosed SEC effectiveness, stockholder approval, and reduced cash balance.
What to watch
Cash fell materially from Dec. 31, 2025 to Sept. 30, 2026, and all clinical development is on hold, which could increase dilution or financing expectations even if the merger advances.
Background
Pulmatrix is a Nasdaq-listed biopharma focused on inhaled therapeutics using its iSPERSE technology and has an announced merger agreement with privately held Eos SENOLYTIX.
Ticker impact
Pulmatrix reports Q3 2026 results and says it has SEC effectiveness and stockholder approval for its merger with Eos SENOLYTIX, targeting year-end close.
Likely upward bias as investors price higher odds of year-end merger completion, partially offset by low cash and clinical development being on hold.
The filing is a primary EDGAR 8-K with merger milestones (SEC effectiveness, stockholder approval) and updated financial position (cash down vs prior year-end) plus a stated plan to license/monetize assets while development is on hold.
Market effects
Biopharma deal-making and inhaled therapeutics licensing narratives may see incremental attention, but impact is company-specific.
Limited, as this is a small-cap US biotech corporate update.
Low; includes India Phase 3 approval context for a partner asset, but the primary tradable catalyst is the US-listed issuer’s merger progress.
Counterpoint
Year-end merger timing still depends on Nasdaq listing approval and a reverse stock split, so the update may not eliminate execution risk.
Key entities
- companyPulmatrix, Inc.
Nasdaq-listed biopharmaceutical company filing the 8-K with Q3 2026 results and merger progress update.
- companyEos SENOLYTIX, Inc.
Privately held biotechnology company that is the target in Pulmatrix’s proposed merger.
- companyCipla Technologies
Partner developing PUR1900 in India, including approval to proceed to Phase 3.
- companyMannKind Corporation
Licensor/partner for iSPERSE technology in certain fields of use.

